S3
To construct pWC45, larA was amplified from pWC44 and malE from pMAL-c2x with each PCR product containing an overlapping region with codons that encode for the Factor Xa Protease recognition site IEGR. The genes were then overlapped together in a second PCR step and cloned via EcoRI and HindIII into pQE-80. To construct pWC46, the malE gene was amplified from pMAL-c2x, with primers that append codons for MIEGR to the N-terminal end.
The PCR product was then cloned via EcoRI and HindIII into pQE-80. To construct LarA-MBP azidophenylalanine variants, forward and reverse primers were designed to introduce a TAG amber stop codon to replace the codon at the desired position in larA. In the first PCR step, the fragment of larA upstream of the mutation site and the fragment of larA-IEGR-malE downstream of the mutation site were amplified from pWC45. The two fragments were then overlapped in a second PCR step, then cloned via EcoRI and HindIII into pQE-80. The construction of LarB1-His 6 azidophenylalanine variants was similar, but cloned into pQE-60 via NcoI and BglII. To construct LarA-MBP variants with truncations of LarA from the N-terminus of the leader peptide, forward primers were designed to exclude the designed number of codons but retaining the ATG start codon and EcoRI site upstream. To construct LarALP-GSSG-MBP and LarACP-GSSG-MBP, larALP/larACP and malE were amplified from pWC45 with primers to include a GSSG linker, overlapped in a second PCR step, then cloned via EcoRI and HindIII into pQE-80.
The astexin-3 cluster in pMM65 has been previously described. 3 The astexin-3 cluster with the AtxB Y41A substitution (pWC89) was cloned by generating the atxB Y41A mutation via overlap PCR (see Table S1 ) and then restriction digested and cloned into pMM65 between the EcoRI and AatII sites.
Protein Expression
All protein expression was done in E. coli strain BL21. All cultures contained 100 mg/L ampicillin to maintain the pQE-based plasmids. For the expression of azidophenylalanine variants, the pQE-based plasmids were co-transformed with pEVOL-pAzF, which contains a tRNA synthetase/tRNA pair for in vivo incorporation of 4-azido-L-phenylalanine in response to the TAG codon 4 . To maintain the pEVOL-pAzF plasmid, 25 mg/L chloramphenicol was added to the cultures in addition to ampicillin.
Expression of LarB1-His 6
LB culture was inoculated with 1:100 volume of an overnight culture and grown at 37 °C, 250 rpm until the OD 600 reached 1. The culture was then induced with 1 mM IPTG and L-phenylalanine (Chem-Impex International) was resuspended in water to 100 mM with a minimal amount of NaOH added dropwise to dissolve the powder. It was then added to the culture to a final concentration of 2 mM. The culture was allowed to shake at 25 °C for 10 minutes, after which it was simultaneously induced with 0.2 wt% arabinose and 1 mM IPTG.
Expression was carried out for 5 hours at 25 °C and 250 rpm, after which the cells were pelleted, resuspended in Column Buffer, and frozen as described above for the expression of the other MBP fusions.
Expression of LarB1-His 6 Azidophenylalanine Variants
The expression conditions for LarB1-His 6 azidophenylalanine variants were the same as for LarA-MBP azidophenylalanine mutants except no glucose was added and expression was carried out for 5.5 hours. The cells were pelleted at 4000 x g for 20 min at 4 °C and stored at -20 °C until purification.
Expression of Astexin-3 Constructs 500 mL of M9 media was inoculated with an overnight culture of pMM65 or pWC89 to a starting OD 600 of 0.02. The cultures were grown at 37 °C, 250 rpm until OD 600 reached 0.25-0.3.
The cultures were then induced with anhydrotetracycline and grown at 20 °C for 20 hours. The cells were pelleted at 4000 x g for 20 min at 4 °C, then washed with 10 mL PBS media. The cells were re-pelleted at 4000 x g for 20 min at 4 °C.
Protein Purification

LarB1-His 6
LarB1-His 6 and its azidophenylalanine-incorporated variants were purified based on Buffer. The diluted lysate was then loaded onto the column. After loading the lysate, the resin was washed twice with 10 column volumes per wash and then eluted with 10 mM maltose in Column Buffer.
Protein Analysis
For all protein purification above, the purity and quantity were first qualitatively assessed via a PAGE gel. The elutions with the highest amounts of protein were pooled together for a total volume of 3 mL, which were then buffer exchanged into 1x PBS buffer (pH 7.4) using Qiagen
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Econo-Pac 10DG desalting columns. The purified proteins were quantified using a Nanodrop spectrophotometer with extinction coefficients calculated by the peptide property calculator provided by Northwestern University with the exception of LarB1-His 6 azidophenylalanine variants; these constructs were measured using a BCA assay (Thermo Scientific Pierce BCA Protein Assay Kit) because of an absorbance irregularity with the Nanodrop due to the unnatural amino acid. BCA assay was also used to measure some LarA-MBP variants and LarB1-His 6 to adjust for the concentration difference obtained using the two quantification methods. In general, the BCA assay measured approximately 60% higher than Nanodrop measurements.
LarA leader peptide
A crude synthesis of LarA leader peptide (LarALP) was purchased from Genscript and then purified via reverse-phase high-performance liquid chromatography (HPLC) using an Agilent LC system (1200 Series) on a semi-preparative column (Zorbax 300SB-C18, 9.4 X 250 mm from Agilent). The crude synthesis powder was resuspended in 10% acetonitrile/water with 0.1% trifluroacetic acid (TFA) to a concentration of approximately 1.7 mg/mL. For each run, 200 μL of the crude synthesis was injected. LarALP was purified using an acetonitrile/water gradient (with 0.1% TFA) from 10% to 50% over 19 minutes starting at the first minute with a 4 mL/min flow rate. The peak at 10 minutes was fraction collected. The collected fractions were then pooled together and frozen at -80 °C for a few hours and then lyophilized (Labconco FreeZone
Freeze Dry System). The lyophilized peptide was then resuspended in 2 mL H 2 O and the concentration was measured with a BCA assay (Pierce BCA Protein Assay Kit) in triplicate. The peptide was then aliquoted, frozen, and lyophilized again as described above.
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Astexin-3
The cell pellets were extracted with 10 mL methanol (MeOH). The crude extracts were dried via rotavap, resuspended in 2 mL H 2 O, then extracted through a 1 mL C8 column. The C8
MeOH extracts were dried via speedvac, then resuspended in 250 μL 50% acetonitrile/50%
water. Production level was measured by HPLC, injecting 10 μL of the samples onto an analytical scale C18 column (Zorbax 300SB-C18, 4.6 × 150 mm). A linear gradient from 10% acetonitrile/water (0.1% TFA) to 50% acetonitrile/water (0.1% TFA) over 20 minutes followed by a linear gradient to 90% acetonitrile/water (0.1% TFA) in 5 minutes was used.
Bio-layer Interferometry Binding Assay
Binding kinetics were measured using bio-layer interferometry with the BLItz System and Ni-NTA biosensors from ForteBio. All samples were prepared so that they were in 1x
Kinetics done with different times of UV exposure, using one well per time point. The reaction products were analyzed using PAGE. Constructs that showed good crosslinking at the standard concentrations (those that were easily visible after about 10 min of UV exposure) were then scaled-up to 40-50 x 75 μL reactions and exposed to UV for 5-7 minutes at a time with a 3-5 minute cooling period in between for a total exposure time of one hour.
Removal of MBP tag and purification of cross-linked peptide
The reactions were then pooled and excess LarB1-His 6 was removed via size exclusion using an Amicon Ultra-4 mL 30 kDa centrifugal filter unit. The reaction was concentrated at 4000 rpm (Thermo Sorvall Legend RT+ centrifuge, swinging bucket rotor) for 10-15 minutes until an approximate volume of 300 μL. Next 4 mL of 20 mM Tris-HCl with 100 mM NaCl and S10 
Trypsin Digestion
First 20 μL of purified LarA-LarB1-His 6 cross-linked peptide was denatured with 20 μL 8M urea, 50 mM Tris-HCl, pH 8.0 at room temperature for ten minutes. The peptide was then diluted five-folds with 50 mM ammonium bicarbonate and digested for 16 hours at 37 °C with 0.1 μg of sequencing grade trypsin (Promega). The digested product was then cleaned up for mass spectrometry using a C18 spin column (Pierce). The standard protocol from Pierce was used, resulting in digested peptide eluted in 40 μL 70% acetonitrile.
Mass Spectrometry
MALDI-TOF
Samples for MALDI-TOF were prepared by mixing 1 μL of trypsin digested peptide 50:50 with 2.5 mg/mL -cyano-4-hydroxycinnamic acid (Sigma) matrix. The sample was prepped in duplicate and spotted onto an Applied Biosystems 384 Opti-TOF 123 mm x 81 mm S11 SS plate and allowed to dry. Molecular weights of digested peptide fragments were determined with an ABI-MDS SCIEX 4800 MALDI-TOF/TOF instrument in positive-ion mode.
LC-MS/MS
The rest of the trypsin digestion was sent to the Princeton University Department of Molecular Biology Proteomics & Mass Spectrometry Core Facility where LC-MS/MS was done using a Thermo Orbitrap Elite or QExactive instrument.
Circular Dichroism
Purified LarB1-His 6 was buffer exchanged into 10 mM potassium phosphate, 100 mM ammonium sulfate buffer (pH 7.3) using an Amicon Ultra-4 mL 3 kDa centrifugal filter unit.
The concentration was measured via a Nanodrop spectrophotometer as described in the protein purification section. The protein was then diluted to 10.5 μM and used for circular dichroism measurements. The blank buffer and protein samples were each measured five times at 20 °C in a 1 mm pathlength cuvette, scanning from 190 nm to 250 nm. The final LarB1 CD spectrum was obtained by averaging the LarB1 spectra and subtracting the average background spectrum.
Docking Model
The LarB1 I-TASSER homology model was first loaded into the standalone version of Table S1 .Primers used in this study. LarALP-GSSG-IEGR-MBP pWC57
Supplementary Tables and Figures
Primer Name
LarA Y28A-MBP pWC58
LarACP-IEGR-MBP pWC60
LarA -10aa-IEGR-MBP (N-terminal truncation) pWC61
LarA -15aa-IEGR-MBP (N-terminal truncation) pWC66
LarA Y32AzF-IEGR-MBP pWC67
LarA W35AzF-IEGR-MBP pWC68
LarA -5aa-IEGR-MBP (N-terminal truncation) pWC71
LarA -9aa-IEGR-MBP (N-terminal truncation) pWC72
LarA Y9AzF-IEGR-MBP pWC73
LarB1 Y28AzF-His 6 pWC74
LarB1 Y29AzF-His 6 pWC75
LarB1 L31AzF-His 6 pWC76
LarB1 N32AzF-His 6 pWC77
LarB1 D27AzF-His 6 pWC78
LarB1 Q30AzF-His 6 pWC79
LarB1 Y16AzF-His 6 pWC80
LarB1 V19AzF-His 6 pMM65
Astexin-3 cluster pWC89
Astexin-3 cluster with AtxB Y41A mutation S16 
